Immunome, Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| IMNM | 4583.T | IDYA | IMTX | BINV.ST | IMCR | |
|---|---|---|---|---|---|---|
| Market cap | 2.30B | 6.73B | 3.12B | 1.05B | 245.45M | 1.51B |
| P/E (TTM) | — | — | — | — | — | — |
| Forward P/E | -7.9 | -2.8 | -7.9 | -3.4 | -0.9 | -37.7 |
| Price/book | 4.2 | 4.2 | 2.9 | 2.1 | 1.2 | 3.6 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | +25.94% | −35.11% | +8.41% | −25.14% | −88.73% | −7.49% |
| Today | −3.89% | −2.35% | +3.29% | −2.33% | +4.04% | −2.66% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 20 min.
Latest news
All IMNM news ›Immunome Presents Additional Clinical Data for Varegacestat in Desmoid Tumors at ESMO 2026
“For patients with desmoid tumors, treatment goals extend beyond tumor shrinkage to include symptom relief and improved physical function,” said Bob Lechleider, M.D., Chief Medical Officer of Immunome. “These presentations build on the…
Recent Investment Analysts’ Ratings Updates for Immunome (IMNM)
Posted by Kim Johansen on Oct 21st, 2026 Immunome (NASDAQ: IMNM) recently received a number of ratings updates from brokerages and research firms: Immunome, Inc (NASDAQ: IMNM) is a clinical-stage biopharmaceutical company focused on…
Arbutus Biopharma (NASDAQ:ABUS) vs. Immunome (NASDAQ:IMNM) Financial Comparison
Posted by Michael Walen on Oct 12th, 2026 Immunome (NASDAQ:IMNM – Get Free Report) and Arbutus Biopharma (NASDAQ:ABUS – Get Free Report) are both healthcare companies, but which is the superior investment? We will compare the two…
Immunome (NASDAQ:IMNM) Stock Price Down 6.6% – What’s Next?
Posted by Michael Walen on Oct 8th, 2026 Immunome, Inc. (NASDAQ:IMNM – Get Free Report) shares dropped 6.6% during mid-day trading on Tuesday. The company traded as low as $19.84 and last traded at $19.7820. Approximately 448,182 shares…
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - October 6, 2026
BioSpace Each stock option has an exercise price per share equal to $20.89, the Company’s closing sales price on October 1, 2026, and will vest over four years, with 25% of the underlying shares vesting on the
More from 1 other outlet
Immunome - Enters Amendment No. 4 To License Agreement With Bristol-Myers Squibb Company On Oct 2, 2026
TradingView Immunome - Enters Amendment No. 4 To License Agreement With Bristol-Myers Squibb Company On Oct 2, 2026
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Most coverage from
- themarketsdaily.com3
- biospace.com1
- stocktitan.net1
- tradingview.com1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 6 articles, not a forecast.